These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31849155)

  • 61. Nicorandil improves clinical outcomes in patients with stable angina pectoris requiring PCI: a systematic review and meta-analysis of 14 randomized trials.
    Li Y; Liu H; Peng W; Song Z
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):855-865. PubMed ID: 30079778
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Intracoronary application of nicorandil regulates the inflammatory response induced by percutaneous coronary intervention.
    Hu K; Wang X; Hu H; Xu Z; Zhang J; An G; Su G
    J Cell Mol Med; 2020 Apr; 24(8):4863-4870. PubMed ID: 32175662
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sustained nicorandil administration reduces the infarct size in ST-segment elevation myocardial infarction patients with primary percutaneous coronary intervention.
    Wang S; Duan Y; Feng X; Liu L; Shi Z; Wang B; Xia C; Man W; Wang H; Zhao Z; Sun D
    Anatol J Cardiol; 2019 Mar; 21(3):163-171. PubMed ID: 30821716
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Utility and Validity of Intracoronary Administration of Nicorandil Alone for the Measurement of Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis.
    Ishibuchi K; Fujii K; Otsuji S; Takiuchi S; Hasegawa K; Tamaru H; Ishii R; Yasuda S; Nakabayashi S; Yamamoto W; Kusumoto H; Taniguchi Y; Kakishita M; Shimatani Y; Higashino Y
    Circ J; 2019 Sep; 83(10):2010-2016. PubMed ID: 31413232
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The effects of nicorandil on microvascular function in patients with ST segment elevation myocardial infarction undergoing primary PCI.
    Kostic J; Djordjevic-Dikic A; Dobric M; Milasinovic D; Nedeljkovic M; Stojkovic S; Stepanovic J; Tesic M; Trifunovic Z; Zamaklar-Tifunovic D; Radosavljevic-Radovanovic M; Ostojic M; Beleslin B
    Cardiovasc Ultrasound; 2015 May; 13():26. PubMed ID: 26012474
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Protective effect of nicorandil on myocardial injury following percutaneous coronary intervention in older patients with stable coronary artery disease: Secondary analysis of a randomized, controlled trial (RINC).
    Kawakita N; Ejiri K; Miyoshi T; Kohno K; Nakahama M; Doi M; Munemasa M; Murakami M; Nakamura K; Ito H;
    PLoS One; 2018; 13(4):e0194623. PubMed ID: 29659585
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Nicorandil suppressed myocardial injury after percutaneous coronary intervention.
    Isono T; Kamihata H; Sutani Y; Motohiro M; Yamamoto S; Kyoui S; Iharada Y; Kurimoto K; Hara K; Takahashi H; Iwasaka T
    Int J Cardiol; 2008 Jan; 123(2):123-8. PubMed ID: 17346816
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cardiovascular magnetic resonance image analysis and mechanism study for the changes after treatments for primary microvascular angina pectoris.
    Huang Q; Wang WT; Wang SS; Pei A; Sui XQ
    Medicine (Baltimore); 2021 May; 100(21):e26038. PubMed ID: 34032727
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Changes of circulating endothelial progenitor cells in patients with coronary heart diseases before and after percutaneous coronary intervention].
    Luo YS; Qian JY; Zhang L; Ma JY; Huang D; Fan B; Ge JB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Feb; 38(2):126-30. PubMed ID: 20398557
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Determinants of coronary events in patients with stable angina: results from the impact of nicorandil in angina study.
    IONA Study Group
    Am Heart J; 2005 Oct; 150(4):689. PubMed ID: 16209965
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial.
    Gutierrez JA; Karwatowska-Prokopczuk E; Murphy SA; Belardinelli L; Farzaneh-Far R; Walker G; Morrow DA; Scirica BM
    Clin Cardiol; 2015 Aug; 38(8):469-75. PubMed ID: 26059896
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of angina prior to acute ST-elevation myocardial infarction on short-term outcomes after primary percutaneous coronary intervention: results from the Shanghai Registry of Acute Coronary Syndrome (SRACE).
    Zhang Q; Zhang RY; Zhu TQ; Hu J; Yang ZK; Ding FH; Du R; Zhu ZB; Shen WF
    Chin Med J (Engl); 2012 Mar; 125(6):977-82. PubMed ID: 22613517
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention.
    Lim SY; Bae EH; Jeong MH; Kang DG; Lee YS; Kim KH; Lee SH; Yoon KH; Hong SN; Park HW; Hong YJ; Kim JH; Kim W; Ahn YK; Cho JG; Park JC; Kang JC
    Circ J; 2004 Oct; 68(10):928-32. PubMed ID: 15459466
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Role of shortened QTc dispersion in in-hospital cardiac events in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
    Lai CC; Hsiao HC; Hsiao SH; Huang WC; Chiou CW; Yeh TC; Hwang HR; Lee D; Mar GY; Lin SK; Chiou KR; Lin SL; Liu CP
    J Chin Med Assoc; 2006 Jul; 69(7):297-303. PubMed ID: 16903642
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Fractional flow reserve in unstable angina and non-ST-segment elevation myocardial infarction experience from the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) study.
    Sels JW; Tonino PA; Siebert U; Fearon WF; Van't Veer M; De Bruyne B; Pijls NH
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1183-9. PubMed ID: 22115657
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristics.
    Ferrari R; Ford I; Fox K; Marzilli M; Tendera M; Widimský P; Challeton JP; Danchin N
    Am Heart J; 2019 Apr; 210():98-107. PubMed ID: 30771737
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Beneficial effects of intracoronary nicorandil on microvascular dysfunction after primary percutaneous coronary intervention: demonstration of its superiority to nitroglycerin in a cross-over study.
    Ito N; Nanto S; Doi Y; Kurozumi Y; Natsukawa T; Shibata H; Morita M; Kawata A; Tsuruoka A; Sawano H; Okada K; Sakata Y; Kai T; Hayashi T
    Cardiovasc Drugs Ther; 2013 Aug; 27(4):279-87. PubMed ID: 23722418
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Meta-analysis of Nicorandil effectiveness on myocardial protection after percutaneous coronary intervention.
    Zhao XT; Zhang CF; Liu QJ
    BMC Cardiovasc Disord; 2019 Jun; 19(1):144. PubMed ID: 31200660
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Nicorandil, a hybrid between nitrate and ATP-sensitive potassium channel opener, preconditions human heart to ischemia during percutaneous transluminal coronary angioplasty.
    Yasuda T; Hashimura K; Matsu-ura Y; Kato Y; Ueda T; Mori I; Kijima Y
    Jpn Circ J; 2001 Jun; 65(6):526-30. PubMed ID: 11407735
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hypertension is associated with increased mortality in patients with ischaemic heart disease after revascularization with percutaneous coronary intervention - a report from SCAAR.
    Saluveer O; Redfors B; Angerås O; Dworeck C; Haraldsson I; Ljungman C; Petursson P; Odenstedt J; Ioanes D; Lundgren P; Völz S; Råmunddal T; Andersson B; Omerovic E; Bergh N
    Blood Press; 2017 Jun; 26(3):166-173. PubMed ID: 28092977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.